@article{27ec43220b964557bea6c75318bd8bb0,
title = "Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis",
abstract = "Objectives: There are few comparative data for tumor necrosis factor inhibitors in patients with rheumatoid arthritis (RA). Methods: Historical data for reference product/biosimilar intravenous infliximab, or adalimumab and etanercept, were pooled and compared with phase 3 study results for a subcutaneous (SC) formulation of the infliximab biosimilar CT-P13, in a systematic review and meta-analysis (PROSPERO: CRD42019149621). Results: The authors identified 13 eligible controlled trials that randomized over 5400 participants to prespecified treatments of interest. Comparison with pooled historical data suggested a numerical advantage for CT-P13 SC over intravenous infliximab for almost every prespecified efficacy outcome evaluated, including Disease Activity Score in 28 joints (C-reactive protein/erythrocyte sedimentation rate), Clinical/Simplified Disease Activity Index scores, American College of Rheumatology responses, and multiple measures of disease remission and low disease activity; for the majority of outcomes, there was no overlap in 95% confidence intervals between groups. A numerical advantage for CT-P13 SC was also observed for safety outcomes (adverse events, infections, and discontinuations). Similar, but less marked, trends were observed for comparison with historical efficacy and safety data for adalimumab/etanercept. Conclusion: CT-P13 SC offers an improved or similar benefit-to-harm ratio compared with infliximab (intravenous) and adalimumab/etanercept, for the treatment of moderate-to-severe RA.",
keywords = "Adalimumab, CT-P13, biosimilar, etanercept, infliximab, rheumatoid arthritis",
author = "Roberto Caporali and Yannick Allanore and Rieke Alten and Bernard Combe and Patrick Durez and Florenzo Iannone and Nurmohamed, {Mike T.} and Lee, {Sang Joon} and Kwon, {Taek Sang} and Choi, {Jean Soo} and Gahee Park and Yoo, {Dae Hyun}",
note = "Funding Information: We would like to thank MinYoung Jang (Celltrion Healthcare), who acted as an independent reviewer for the selection of studies included in the review. Medical writing support (including development of a draft outline and subsequent drafts in consultation with the authors, assembling tables and figures, collating author comments, copyediting, fact checking and referencing) was provided by Beatrice Tyrrell, DPhil, at Aspire Scientific Limited (Bollington, UK), and funded by Celltrion Healthcare (Incheon, Republic of Korea). Funding Information: R Caporali has received speaker{\textquoteright}s fees and consultation fees from AbbVie, BMS, Celltrion, Fresenius-Kabi, Gilead-Galapagos, Lilly, MSD, Pfizer, Roche, Samsung-Bioepis, Sanofi, and UCB. Y Allanore has no competing interests to disclose. R Alten has received honoraria from AbbVie, Bristol-Myers Squibb, Celltrion, Gilead, Janssen, Lilly, Merck, Novartis, Pfizer, Roche-Chugai and UCB; and research grants from Novartis, Pfizer, and Roche. B Combe has received honoraria from AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Lilly, Merck, Novartis, Pfizer, Roche-Chugai, Sanofi and UCB; and research grants from Novartis, Pfizer, and Roche. P Durez has received speaker{\textquoteright}s fees from AbbVie, BMS, Galapagos, Lilly, and Sanofi. F Iannone has received speaker{\textquoteright}s fees and consultation grants from AbbVie, Actelion, BMS, Biogen, Lilly, MSD, Pfizer, Roche, Sanofi, and UCB. MT Nurmohamed has received consulting fees from AbbVie, Celgene, Celltrion, Eli Lilly, Janssen, and Sanofi; speaker{\textquoteright}s fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Roche, and Sanofi; and research funding from AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, MSD, Mundipharma, Novartis, Pfizer, Roche, and Sanofi. SJ Lee and G Park are employed full time by Celltrion Inc. TS Kwon and JS Choi are employed full time by Celltrion Healthcare. DH Yoo has received speaker{\textquoteright}s fees and consultation fees from Celltrion Healthcare and Celltrion Inc. Publisher Copyright: {\textcopyright} 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",
year = "2021",
month = jan,
doi = "https://doi.org/10.1080/1744666X.2020.1858803",
language = "English",
volume = "17",
pages = "85--99",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "1",
}